WORLD US announces anti-malarial drug trial against COVID-19 in Detroit hospital

WORLD

US announces anti-malarial drug trial against COVID-19 in Detroit hospital

Xinhua

12:30, April 06, 2020

plaquenil.jpg

A box of Plaquenil, the brand name of hydroxychloroquine, is displayed on March 30, 2020 in Paris, France. (Photo: AP)

WASHINGTON, April 5 (Xinhua) -- The anti-malarial drug hydroxychloroquine will be used in a trial covering 3,000 patients at a hospital in Detroit, Michigan, and the results will be tracked in a formal study, said U.S. Vice President Mike Pence on Sunday.

Pence told a White House briefing that they are "more than prepared" to make hydroxychloroquine available to doctors' offices and pharmacies in the Detroit area.

US President Donald Trump said the federal government has stockpiled 29 million doses of hydroxychloroquine.

Last week, Trump said hydroxychloroquine was being administered to 1,100 patients in New York along with Z-Pak, or azithromycin.

Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, told the White House briefing on Saturday there was no "definitive information to be able to make any comment" on whether the drug can be used to treat coronavirus.

The United States is stepping up the development of treatments for COVID-19 patients, including experimenting with hydroxychloroquine and blood-related therapies, as confirmed cases and death toll continue to rise.

The number of COVID-19 cases in the United States reached 337,072 as of 0100 GMT Monday, with 9,619 deaths, according to the Center for Systems Science and Engineering at Johns Hopkins University.


Related Stories

Terms of Service & Privacy Policy

We have updated our privacy policy to comply with the latest laws and regulations. The updated policy explains the mechanism of how we collect and treat your personal data. You can learn more about the rights you have by reading our terms of service. Please read them carefully. By clicking AGREE, you indicate that you have read and agreed to our privacy policies

Agree and continue